This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (January 11, 2018)


To Our Investors

Thank you for continuously supporting Japan Tissue Engineering (J-TEC).

Starting activities to leap ahead

Ken-ichiro Hata
President & CEO Ken-ichiro Hata

It is 2018, and we have entered a new cycle.

Last year was a year of changes for J-TEC. In March 2017, under the leadership of our previous CEO, we reached profitability for the first time in the company’s history. We also launched our Custom Development and Manufacturing Business, increasing our efforts in popularizing regenerative medicine through the alliances we have established with academic scientists and companies that possess seeds of innovative technology. Although slowly, this new business is steadily gaining ground.

As we enter the New Year, we started the activities that will help us take a leap further ahead. Following our slogan from 2017, “J-TEC, daring to leap ahead”, we will continue to take on new challenges.

At our New Year’s address, I invited my employees to “make J-TEC a good, rewarding company” and created the opportunity to think about what makes a company a good and rewarding one. Our mission is not only to offer high value products and services, but also to popularize regenerative medicine in the society. What should we do to make J-TEC a “good, rewarding company” for our shareholders and employees? Where does the value of our company lie? During this year, I would like to think about these questions. In addition to achieving the following three goals I announced at the time I assumed the company’s presidency, I would also like to “create a good and rewarding company” with the collaboration of you all.

1. Further consolidation of regenerative medical products into medical treatment

Up to now, we have concentrated efforts to ensure that the autologous cultured epidermal JACE, and the autologous cultured cartilage JACC, would reach as many patients as fast as possible. Moreover, following the approval of an additional indication, JACE is now used not only to treat patients with extensive burns, but also children with Giant Congenital Melanocytic Nevus. However, we still need to increase awareness of regenerative medicine among the public and medical professionals. I believe that educating and delivering our products to patients who are in need of this medical care is our primary mission.

2. Enhance synergy with Fujifilm Group

The resources I was able to tap in my time within the Fujifilm Group are extremely important to further promote our business. High-performance material development technology, image analysis technology, and cell culture automation technology are indispensable for the future of regenerative medicine. Additionally, companies like Cellular Dynamics International and its iPS cell technology, and Wako Pure Chemicals and its know-how on cell culture media are also essential partners in the advancement of regenerative medicine. As someone who sees himself as a technologist, I will work to ensure these technological synergies blossom.

3. Educating the public

We will need to increase the number of people well-versed in regenerative medicine in order to accelerate its implementation, and create markets. Starting from J-TEC’s employees, we will strive to educate the public in regenerative medicine.

January 11, 2018
Kenichiro Hata
President & CEO
Japan Tissue Engineering Co., Ltd.